How Much Does Retatrutide Cost in Vermont in 2026?

What Is the List Price for Retatrutide in Vermont?

Eli Lilly's manufacturer list price for retatrutide places it in the range of $1,000 per month for the once-weekly subcutaneous injection, consistent with the pricing tier of other incretin-class obesity medications on the market. Vermont retail pharmacies generally sell at or near list price for uninsured cash-pay patients.

This figure tracks closely with tirzepatide (Zepbound), which Eli Lilly priced at $1,059.87 per month at its 2023 launch. Retatrutide's positioning as a triple agonist (targeting GIP, GLP-1, and glucagon receptors simultaneously) gives Lilly room to price at a modest premium, though competition from semaglutide and tirzepatide constrains the ceiling. Vermont has no state-level drug price cap for branded weight-management medications, so the final shelf price depends on the dispensing pharmacy's markup and any negotiated rates with pharmacy benefit managers (PBMs).

For Vermonters paying entirely out of pocket, the annual cost can exceed $12,000. That number drops significantly with insurance, manufacturer coupons, or compounded alternatives. Each of those options carries different eligibility rules and trade-offs covered below.

How Vermont Medicaid Handles Retatrutide

Vermont Medicaid covers retatrutide for chronic weight management, but only with prior authorization (PA). The PA process requires documentation of medical necessity, which in practice means the prescribing clinician must show a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnea.

The state's Department of Vermont Health Access (DVHA) manages the preferred drug list. Retatrutide's placement on this list determines whether Medicaid requires step therapy (trying a less expensive agent first) before approving coverage. As of mid-2026, Vermont Medicaid's step therapy protocols for obesity pharmacotherapy typically require documented failure or intolerance of at least one prior GLP-1 receptor agonist.

PA turnaround in Vermont averages 3 to 5 business days. Denials can be appealed through the DVHA fair hearing process. Clinicians familiar with the PA workflow can often secure approval on the first submission by including a recent A1C or metabolic panel, a weight history showing prior intervention attempts, and documentation of comorbidities.

Medicaid enrollees approved through PA pay zero or near-zero copays for retatrutide in Vermont. That makes Medicaid the single most cost-effective pathway for eligible residents.

Private Insurance Coverage in Vermont

Commercial insurers operating in Vermont, including Blue Cross Blue Shield of Vermont, MVP Health Care, and Cigna, have begun adding retatrutide to formularies, though coverage terms vary by plan. Most require prior authorization and medical documentation similar to Medicaid's criteria.

Employer-sponsored plans show the widest variation. Self-insured employer plans (governed by federal ERISA law rather than Vermont state mandates) are not required to follow the state's essential health benefit benchmarks. Some self-insured employers exclude obesity medications entirely. Others cover them with high specialty-tier copays of $150 to $300 per month.

Vermont's fully insured individual and small-group plans must comply with the state's essential health benefit requirements, which have gradually expanded to include pharmacotherapy for obesity as a recognized chronic disease. Vermonters shopping on Vermont Health Connect during open enrollment should check formulary documents closely: the tier placement of retatrutide determines whether the copay is $25 or $250.

A practical first step: call the number on the back of your insurance card and ask the pharmacy benefits team whether retatrutide carries PA requirements and what tier it sits on. This five-minute call can save weeks of surprise denials.

Is Compounded Retatrutide Legal in Vermont?

Yes. Compounded retatrutide is available to Vermont residents through licensed 503A compounding pharmacies. These pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits patient-specific compounding based on a valid prescription.

Vermont's Board of Pharmacy requires that out-of-state 503A pharmacies register with the state before shipping compounded medications to Vermont addresses. This registration requirement adds a layer of oversight that not all states enforce. Vermonters should verify that any compounding pharmacy they use holds a current Vermont nonresident pharmacy license.

Compounded retatrutide typically costs between $300 and $500 per month, depending on the dose and the pharmacy's pricing structure. The lower cost reflects the absence of brand-name patent licensing fees, though the trade-off is that compounded products do not undergo the same FDA manufacturing review as brand-name drugs. Purity and potency can vary between compounders.

The American Association of Clinical Endocrinology (AACE) has advised caution with compounded peptides, noting that patients should confirm third-party testing (such as USP or ISO 17025 certification) and verify the pharmacy's inspection history. Vermont residents can check a pharmacy's license status through the Vermont Secretary of State's Office of Professional Regulation.

How Much Can the Eli Lilly Savings Card Save Vermont Patients?

Eli Lilly offers a manufacturer savings card for retatrutide that can reduce the out-of-pocket cost to as little as $25 per month for eligible commercially insured patients. The card covers the gap between the patient's insurance copay and the $25 target, up to a maximum annual benefit.

Eligibility requirements exclude patients on government insurance (Medicaid, Medicare, Tricare, VA). Commercially insured Vermonters with a valid prescription can enroll online or through their prescriber's office. The card works at most retail pharmacies in Vermont, including chains like CVS, Walgreens, Kinney Drugs, and independent pharmacies that accept manufacturer copay cards.

Uninsured patients may qualify for Lilly's separate patient assistance program, which provides the medication at no cost to individuals below 400% of the federal poverty level (roughly $62,400 for a single-person household in 2026). The application requires income documentation and prescriber attestation.

One caveat: savings cards do not count toward insurance deductibles or out-of-pocket maximums in most plan designs. Patients relying on the card to manage costs should factor this into their annual budgeting, particularly if they have a high-deductible health plan.

The Clinical Case for Retatrutide: Trial Data

Retatrutide's efficacy data comes primarily from the phase 2 trial published in the New England Journal of Medicine by Jastreboff et al. (2023). In that study (N=338), participants receiving the highest dose of retatrutide (12 mg weekly) achieved a mean body weight reduction of 24.2% at 48 weeks, compared to 2.1% in the placebo group.

That 24.2% figure stands out. For context, semaglutide 2.4 mg (Wegovy) produced 14.9% mean weight loss at 68 weeks in the STEP-1 trial (N=1,961). Tirzepatide 15 mg (Zepbound) produced up to 22.5% mean weight loss at 72 weeks in SURMOUNT-1 (N=2,539). Retatrutide's triple-agonist mechanism, which adds glucagon receptor activation to the GIP/GLP-1 activity of tirzepatide, appears to drive this incremental benefit through increased energy expenditure and hepatic fat mobilization.

Dr. Ania Jastreboff of Yale School of Medicine, lead author on the phase 2 trial, noted: "The magnitude of weight reduction seen with retatrutide at the highest doses exceeded what we have observed with currently available agents targeting one or two incretin pathways."

Phase 3 trials (the TRIUMPH program) are evaluating retatrutide across multiple indications, including obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD). The TRIUMPH-3 obesity trial enrolled over 1,800 participants across North American sites, including academic centers in the northeastern United States.

Common side effects mirror those of other incretin-class drugs: nausea (reported in 16% to 43% of participants by dose), diarrhea, vomiting, and decreased appetite. Nausea was most frequent during dose escalation and tended to decrease after the first 4 to 8 weeks of treatment [1].

Getting Retatrutide via Telehealth in Vermont

Vermont permits telehealth prescribing of retatrutide. The state's telehealth parity laws, updated in 2024, require that insurers cover telehealth visits at the same rate as in-person visits, removing a historical barrier to remote obesity care.

Telehealth platforms that employ clinicians licensed in Vermont can prescribe retatrutide after a synchronous video or audio evaluation. The prescribing clinician must complete a standard medical history, review lab work (typically a metabolic panel and thyroid function), and confirm the absence of contraindications such as personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Vermont residents in rural areas, including the Northeast Kingdom, Lamoille Valley, and southern Bennington County, benefit disproportionately from telehealth access. The nearest endocrinology or obesity medicine specialist may be 60 to 90 minutes away in these regions. Telehealth closes that gap without requiring time off work or long drives.

Prescriptions written via telehealth can be sent to any Vermont-licensed pharmacy, including mail-order and compounding pharmacies. Some telehealth platforms bundle medication fulfillment with the consultation, simplifying the process to a single transaction.

How to Find the Cheapest Retatrutide in Vermont

The lowest-cost path depends on your insurance status. Here is the decision tree by coverage type.

Medicaid enrollees: File for prior authorization through your prescriber. If approved, your out-of-pocket cost is zero or a nominal copay of $1 to $3.

Commercially insured (brand preferred): Check your formulary tier, then apply for the Eli Lilly savings card. Combined with insurance, your monthly cost may drop to $25.

Commercially insured (brand not covered or high copay): Request a formulary exception or appeal. If denied, compare the savings-card price for brand-name retatrutide against the cash price for compounded retatrutide. The savings card may still be cheaper.

Uninsured, income below 400% FPL: Apply to Eli Lilly's patient assistance program for free medication.

Uninsured, income above 400% FPL: Compounded retatrutide from a Vermont-licensed 503A pharmacy at $300 to $500 per month is typically the most affordable option. Compare prices across at least two compounders; pricing varies by 20% to 40%.

GoodRx, RxSaver, and similar discount-card platforms may also carry negotiated cash prices at Vermont retail pharmacies, though these rarely beat the manufacturer savings card for insured patients. Discount cards are most useful for uninsured patients comparing brand-name cash prices across different pharmacy chains.

Retatrutide vs. Other Weight-Loss Medications: Vermont Cost Comparison

Vermont residents weighing retatrutide against alternatives should consider both efficacy and monthly cost. A side-by-side view based on approximate 2026 pricing in the state:

Semaglutide 2.4 mg (Wegovy): List price approximately $1,350 per month. Mean weight loss 14.9% at 68 weeks (STEP-1). Covered by most Vermont commercial plans and Medicaid with PA.

Tirzepatide 15 mg (Zepbound): List price approximately $1,060 per month. Mean weight loss up to 22.5% at 72 weeks (SURMOUNT-1). Growing formulary inclusion in Vermont.

Retatrutide 12 mg: List price approximately $1,000 per month. Mean weight loss 24.2% at 48 weeks (Jastreboff et al. phase 2). Vermont Medicaid covers with PA.

The Endocrine Society's 2024 clinical practice guideline on obesity pharmacotherapy recommends selecting agents based on a patient's metabolic profile, comorbidity burden, and cost constraints rather than efficacy data alone. A patient with concurrent type 2 diabetes and MASLD might benefit from retatrutide's glucagon receptor activity more than from semaglutide's GLP-1-only mechanism, even if the monthly cost is comparable.

What Vermont Patients Should Know Before Starting

Before filling a retatrutide prescription in Vermont, confirm three things with your prescriber. First, verify that your baseline labs (fasting glucose, lipid panel, hepatic function, thyroid panel) are current within the last 90 days. Second, confirm the dose-escalation schedule: retatrutide titrates from a starting dose upward over several weeks to minimize gastrointestinal side effects, and skipping the ramp exposes patients to unnecessary nausea risk [1]. Third, ask whether your prescriber will monitor you at 4-week intervals during titration or defer to less frequent follow-up. The American Gastroenterological Association's 2024 guidance recommends at least monthly check-ins during the first 12 weeks of any incretin-based obesity therapy, with labs repeated at week 12 and week 24.